Daniela A Bota

Picture of Daniela A Bota
Vice Dean, Clinical Research, School of Medicine
Director, UCI Alpha Clinic, Sue and Bill Gross Stem Cell Research Center
Professor, Department of Neurology, School of Medicine
M.D., Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, 1997
Ph.D., University of Southern California, 2003, Molecular Biology
United Council for Neurologic Subspecialties, 2011, Neuro-Oncology
Phone: (949) 824-6340
Fax: (714) 456-6894
Email: dbota@hs.uci.edu
University of California, Irvine
UC Irvine School of Medicine
1001 Health Sciences Road
835 Irvine Hall, Suite 233
Irvine, CA 92697
Research Interests
Neuro-oncology
Awards and Honors
Physician of Excellence, OCMA: 2020, 2019, 2016
Top Doctors,OC Physicians, As Among the Most Accomplished & Caring, Orange Coast Magazine 2019
ARIISE Awards 2018
Physician of Excellence Award, Orange Coast Magazine, 2017
GBM's Hero's Novocure, 2016
UCI Dean's Physicvian Award 2014
UCI Exceptional Communicator Award 2014
UCI NCI Clinician Award 2012
UCI Stewardship Stard Award 2011, 2010
National Association of Women Business Owners Award 20090


A
Short Biography
Daniela Bota, MD, PhD is the Vice Dean for Clinical Research and the Clinical Director for the Sue & Bill Gross Stem Cell Research Center.

Dr. Bota’s academic research and clinical practice focus on innovative treatments for brain malignancies. She currently serves as a principal investigator for numerous studies including novel glioblastoma stem-cell targeted chemotherapy agents, cellular immunotherapy studies, and wearable devices. She consults for multiple companies involved in developing drugs, cellular therapies, and devices for human use.
Publications
Bota DA, Taylor TH, Piccioni DE, Duma CM, LaRocca RV, Kesari S, Carrillo JA, Abedi M, Aiken RD, Hsu FPK, Kong XT, Hsieh C, Bota PG, Nistor GI, Keirstead HS, Dillman RO. Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. J Exp Clin Cancer Res. 2022 Dec 14;41(1):344. PMID: 36517865

Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, Ma Y, Lu W, Peng S, Wang CL, Yuen B, Dalmas O, Heeringa K, Sennino B, Conroy A, Bethune MT, Mende I, White W, Kukreja M, Gunturu S, Humphrey E, Hussaini A, An D, Litterman AJ, Quach BB, Ng AHC, Lu Y, Smith C, Campbell KM, Anaya D, Skrdlant L, Huang EY, Mendoza V, Mathur J, Dengler L, Purandare B, Moot R, Yi MC, Funke R, Sibley A, Stallings-Schmitt T, Oh DY, Chmielowski B, Abedi M, Yuan Y, Sosman JA, Lee SM, Schoenfeld AJ, Baltimore D, Heath JR, Franzusoff A, Ribas A, Rao AV, Mandl SJ. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2022 Nov 10. PMID: 36356599

Bota DA, Taylor TH, Lomeli N, Kong XT, Fu BD, Schönthal AH, Singer S, Blumenthal DT, Senecal FM, Linardou H, Rokas E, Antoniou DG, Schijns VEJC, Chen TC, Elliot J, Stathopoulos A. A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide. Front Oncol. 2022 Jun 28;12, PMID: 35837107

Bota DA, Mason W, Kesari S, Magge R, Winograd B, Elias I, Reich SD, Levin N, Trikha M, Desjardins A. Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. Neurooncol Adv, 2021 Oct 2;3(1), PMID: 34729484

Lomeli N, Lepe J, Gupta K, Bota DA. Cognitive complications of cancer and cancer-related treatments - Novel paradigms. Neurosci Lett. 2021 Apr 1;749:135720. PMID: 33582187

Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao AR, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020 Dec 1;6(12):1939-1946. PMID: 33119048

Reardon DA, Desjardins A, Vredenburgh JJ, O’Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Cruickshank S, Vitale L, He Y, Green JA, Yellin MJ, Turner CD, Keler T, Davis TA, Sampson JH; ReACT trial investigators. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clin Cancer Res. 2020 Apr 1;26(7):1586-1594. PMID: 32034072

Brown TJ, Bota DA, van Den Bent MJ, Brown PD, Maher E, Aregawi D, Liau LM, Buckner JC, Weller M, Berger MS, Glantz M. Management of low-grade glioma: a systematic review and meta-analysis. Neurooncol Pract. 2019 Jul;6(4):249-258. PMID: 31386075

Schijns VEJC, Pretto C, Strik AM, Gloudemans-Rijkers R, Deviller L, Pierre D, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FPK, Hofman FM, Chen TC, Zidovetzki R, Bota DA, Stathopoulos A. Therapeutic Immunization against Glioblastoma. Int J Mol Sci. 2018 Aug 27;19(9):2540. PMID: 30150597

Bota DA, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FP, Schönthal AH, Hofman FM, Chen TC, Zidovetzki R, Pretto C, Strik A, Schijns VE, Stathopoulos A. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts. CNS Oncol. 2018 Jul 1;7(3). PMID: 30157683

John T, Lomeli N, Bota DA. Systemic cisplatin exposure during infancy and adolescence causes impaired cognitive function in adulthood. Behav Brain Res. 2017 Feb 15;319:200-206. Epub 2016 Nov 13. PMID: 27851909

Di K, Lloyd GK, Abraham V, MacLaren A, Burrows FJ, Desjardins A, Trikha M, Bota DA. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neuro Oncol. 2016 Jun;18(6):840-8. PMID: 26681765

Di K, Lomeli N, Wood SD, Vanderwal CD, Bota DA. Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma. Oncotarget. 2016 Nov 22;7(47):77457-77467. PMID: 27764809

Schijns VEJC, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC, Mespouille P, Hantos P, Glorieux P, Bota DA, Stathopoulos A. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine. 2015 May 28;33(23):2690-6. PMID: 25865468

Bota DA, Alexandru-Abrams D, Pretto C, Hofman FM, Chen TC, Fu B, Carrillo JA, Schijns VE, Stathopoulos A. Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. Perm J. 2015 Spring;19(2):41-6. PubMed Central PMCID: PMC4403580
Grants
ASC Seed Award
National Institutes of Health (NIH), "The Mechanisms of Chemotherapy Induced Cognitive Defects" 2011-2012
Professional Societies
Society of Neuro-Oncology
American Society of Clinical Oncology
American Academy of Neurology
American Medical Association
American Association of Cancer Research
American Association of Neurological Surgeons & the Congress of Neurological Surgeons
Medical Oncology Association of Southern California
Romanian Society of Oncology
Society for Immunotherapy of Cancer
Other Experience
Medical Director, Center for Clinical Research
University of California, Irvine - School of Medicine 2019—2022
Graduate Programs
Cellular and Molecular Biosciences
Interdepartmental Neuroscience Program
Research Centers
Sue & Bill Gross Stem Cell Research Center
Bota Laboratory | https://faculty.sites.uci.edu/botalab/
Last updated
05/11/2023